Hovione has named Mike Ironside as General Manager of its Technology Transfer Center (TTC), which is located in New Jersey. Ironside was most recently with Anacor Pharmaceuticals and has previously worked for GSK and AMRI. Hovione VP of Corporate R&D Thomas Eisele said, "This is a key appointment at an important time for Hovione. We are certain that Dr. Ironside's … [Read more...] about Hovione appoints new General Manager of its Technology Transfer Center
News
Positive Phase 3 results for QVA 149, filings expected by the end of the year
According to Novartis, the latest Phase 3 study of the QVA149 indacaterol/glycopyrronium DPI demonstrated a significant reduction in exacerbations of moderate-to-severe COPD compared to the Seebri Breezhaler glycopyrronium bromide DPI alone. The company says that it plans to submit regulatory filings in Europe and Japan by the end of 2012 and in the US at the end of … [Read more...] about Positive Phase 3 results for QVA 149, filings expected by the end of the year
Liquidia hires Benjamin Yerxa as Chief Scientific Officer
Particle manufacturing specialist Liquidia Technologies has named Benjamin Yerxa, most recently at Clearside Biomedical, as its new Chief Scientific Officer. Yerxa will oversee R&D, "including a focus on scientific collaborations," for the company. Liquidia's PRINT nanofabrication technology can produce particles of specified sizes and shapes for inhalation powders … [Read more...] about Liquidia hires Benjamin Yerxa as Chief Scientific Officer
GSK to submit applications for UMEC/VI inhaler this year
GlaxoSmithKline says that it will begin regulatory submissions for its umeclidinium bromide (UMEC) and vilanterol (VI) dry powder inhaler for the treatment of COPD by the end of 2012. GSK is partnered with Theravance on this product, which will be delivered by the Ellipta inhaler. The two companies also announced the completion of the Phase 3 clinical program. … [Read more...] about GSK to submit applications for UMEC/VI inhaler this year
Hovione hires Conrad Winters as Director of Drug Product Development
Hovione has announced the appointment of Conrad Winters as Director, Drug Product Development. Winters most recently was Senior Director of the Compound Properties Group at Xenon Pharmaceuticals and previously held positions with Merck. Hovione VP of Corporate Research & Development Thomas Eisele commented, "We are very pleased to welcome Dr. Winters to Hovione. … [Read more...] about Hovione hires Conrad Winters as Director of Drug Product Development
Alexza gets EU GMP certificate for Adasuve manufacturing facility
Alexza Pharmaceuticals has received a EU Certificate of GMP Compliance of a Manufacturer subsequent to a May 2012 inspection by the Agencia Espanola de Medicamentos y Productos Sanitarios, the company has announced. Alexza plans to manufacture Adasuve Staccato loxapine at the facility in Mountain View, CA. Alexza says that the initial certificate will remain valid … [Read more...] about Alexza gets EU GMP certificate for Adasuve manufacturing facility
Bend Research opens new spray drying facility
Bend Research has announced the addition of a new stand-alone cGMP spray-drying facility for high potency drug development and manufacturing, including inhalation biotherapeutics. The company offers a range of development and particle engineering services for OINDPs. Bend Research CEO Rod Ray said, “We’re excited to offer our clients expanded cGMP spray-drying … [Read more...] about Bend Research opens new spray drying facility
Positive Phase 3 results for Inavir DPI to prevent flu
Daiichi Sankyo has announced positive Phase 3 results for its Inavir laninamivir octanoate hydrate dry powder inhaler as a prophylactic antiviral. According to the company, the study found that Inavir produced statistically significant reductions in influenza infection compared to placebo among household members in contact with patients infected with influenza A or B, … [Read more...] about Positive Phase 3 results for Inavir DPI to prevent flu
Research firm predicts global asthma and COPD market will reach $47 billion by 2017
A new research report titled "Global Markets for Asthma & COPD Drugs" from RnRMarketResearch.com projects that the global market for prescription asthma and COPD drugs will rise from almost $35 billion in 2011 to $38 billion in 2012 and just over $47 billion in 2017. The report predicts that asthma drug sales alone will reach $20.2 billion in 2017, up from $15.3 … [Read more...] about Research firm predicts global asthma and COPD market will reach $47 billion by 2017
Nephron announces launch of OTC asthma inhalation product
Florida-based Nephron Pharmaceuticals has announced that it is launching an over-the-counter racepinephrine inhalation solution delivered by a device called the EZ Breathe Atomizer. The product will be marketed as Asthmanefrin and is being promoted as a substitute for the banned CFC Primatene Mist inhaler. According to the company, the product will be available at … [Read more...] about Nephron announces launch of OTC asthma inhalation product